Literature DB >> 1987271

Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex.

C R Kensil1, U Patel, M Lennick, D Marciani.   

Abstract

Saponins were purified from Quillaja saponaria Molina bark by silica and reverse phase chromatography. The resulting purified saponins were tested for adjuvant activity in mice. Several distinct saponins, designated QS-7, QS-17, QS-18, and QS-21, were demonstrated to boost antibody levels by 100-fold or more when used in mouse immunizations with the Ag BSA and beef liver cytochrome b5. These purified saponins increased titers in all major IgG subclasses. To determine optimal dose in mice for adjuvant response, QS-7 and QS-21 were tested in a dose-response study in intradermal immunization with BSA in mice; for both of these purified saponins, adjuvant response (determined by stimulation of ELISA titers to BSA) neared maximum at doses of 5 micrograms and was shown to plateau up to the highest dose tested, 80 micrograms. These purified saponins vary considerably in their toxicity, as assessed by lethality in mice; the main component, QS-18, being the most toxic. Saponins QS-7 and QS-21 showed no or very low toxicity in mice, respectively. None of these saponins stimulated production of reaginic antibodies. The monosaccharide composition of these saponins showed similar but distinct compositions with all four containing fucose, xylose, galactose and glucuronic acid. Predominant differences were observed in the quantities of rhamnose, arabinose, and glucose. Monomer m.w. (determined by size exclusion HPLC) were determined to range from 1800 to 2200.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987271

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  103 in total

1.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

2.  Prevention of rotavirus infections in vitro with aqueous extracts of Quillaja Saponaria Molina.

Authors:  Michael R Roner; Ka Ian Tam; Melody Kiesling-Barrager
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

Review 3.  Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity.

Authors:  Nikolai Petrovsky
Journal:  Vaccine       Date:  2006-04-12       Impact factor: 3.641

4.  Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.

Authors:  Yong-Jae Kim; Pengfei Wang; Mauricio Navarro-Villalobos; Bridget D Rohde; JohnMark Derryberry; David Y Gin
Journal:  J Am Chem Soc       Date:  2006-09-13       Impact factor: 15.419

5.  Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.

Authors:  I Mbawuike; Y Zang; R B Couch
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

6.  Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.

Authors:  Brian H Kushner; Irene Y Cheung; Shakeel Modak; Kim Kramer; Govind Ragupathi; Nai-Kong V Cheung
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

7.  Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

Authors:  K Kitamura; P O Livingston; S R Fortunato; E Stockert; F Helling; G Ritter; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Design and synthesis of potent Quillaja saponin vaccine adjuvants.

Authors:  Michelle M Adams; Payal Damani; Nicholas R Perl; Annie Won; Feng Hong; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  J Am Chem Soc       Date:  2010-02-17       Impact factor: 15.419

10.  Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines.

Authors:  M P Jiménez de Bagüés; P H Elzer; J M Blasco; C M Marín; C Gamazo; A J Winter
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.